<DOC>
	<DOC>NCT00067041</DOC>
	<brief_summary>Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.</brief_summary>
	<brief_title>Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Patients with critical limb ischemia and an appropriate reference lowerlimb ischemic wound due to documented peripheral arterial disease who have had an autogenous vein infrainguinal bypass graft performed immediately prior to study initiation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Autogenous Bypass Graft</keyword>
	<keyword>CLI</keyword>
</DOC>